Triumpharma Inc. is a pioneer in developing systems and solutions for advanced drug delivery. We strive to bridge the gap between life science and modern healthcare.

Triumpharma Inc. develops technologies that enhance the performance of many of today's commonly available pharmaceutical products and new chemical entities that give raise to challenging bioavailability problems.

Triumpharma has strong technical capabilities to take products from feasibility to pilot scale. Triumpharma conducts formulation optimization studies, pre-clinical trials on animals, human clinical studies including bioavailability/ bioequivalence trial complying with the international guidelines. The company's core advantages are its extremely low-cost base, experienced staff with multi national experience, holding PhDs from western universities, high-quality research, a large pool of patient’s and volunteers, and fast formulation development meeting the necessary regulatory requirements.

Triumpharma houses a fully GLP-compliant bioanalytical facility with state-of-the-art infrastructure managed by qualified and expert staff with experience in more than 150 different drug development and analysis.

The details of the bioanalytical infrastructure are as follows

  1. Sample processing areas equipped to handle light-sensitive drugs
  2. Instrument lab with HPLCs (ThermoFinnigan) coupled with fluorescence detectors
  3. Instrument lab with LC/MS/MS machines (Sciex API 3000 and Sciex API 4000)
  4. Centrifuges, sample condenser, ph meters, sample shaker and other facilities are available.
  5. Sample storage (with  -20°C and -80°C deep freezers)
  6. Ellix 35-clinical water purification system
  7. Safety system for the laboratory instruments with uninterrupted power supply (UPS) and generator back-up. In addition all records and documents and back up are archived in a secure place.

This publication has been produced with the assistance of the European Union in cooperation with Jordan Enterprise Development Corporation. *

* The contents of this publication are the sole responsibility of Triumpharma and can in no way betaken to reflect the views of the European Union & Jordan Enterprise Development Corporation